Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)
Clinical trial NCT03407170 · TERMINATED
Trial details
- NCT number
- NCT03407170
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-28
- Primary completion
- 2019-08-14
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.